MYX 0.66% $4.60 mayne pharma group limited

Ann: 2019 Full Year Results Investor Presentation, page-18

  1. 1,839 Posts.
    lightbulb Created with Sketch. 272
    I thought the results were quite good when compared against the market sentiment, and i think that is reflected in the roughly 10% bounce today.

    I also liked the increasing profitability of the unique product lines, and the company has said a couple times FY20 (now) will be better than the last and singled out a couple unique products for special mention.

    Markets are always looking forward for the good, and/or bad news, and i get the feeling MYX has finally turned that corner;

    - Strong growth from Specialty Brands with sales and gross profit doubling;
    - Business positioned for a stronger FY20 driven by growth of TOLSURA and LEXETTE,accelerated growth of Metrics Contract Services, new generic product launches and improvedoperating performance.

    Geopolitical factors allowing, i think we'll rise slowly and steadily into the FY20 results.
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.